Korean J Urol.  2008 Nov;49(11):1003-1006. 10.4111/kju.2008.49.11.1003.

Long Term Effectiveness of Doxazosin in Men with Lower Urinary Tract Symptoms Suggesting of Benign Prostatic Hyperplasia

• Choi J
• Lee JO
• Han BH
• Chang HS

• KMID: 1328172
• DOI: http://doi.org/10.4111/kju.2008.49.11.1003

Abstract

PURPOSE: The aim of this study was to evaluate the efficacy of doxazosin over 6 years in men with benign prostatic hyperplasia(BPH).
MATERIALS AND METHODS
This retrospective study enrolled 33 patients with symptomatic BPH who were prescribed an alpha-blocker from January 1999 to December 2000. We evaluated the changes of International Prostate Symptom Score(IPSS), maximal flow rate(Qmax), quality of life(QoL) and residual urine volume(RUV) between before and after 6-year of treatment.
RESULTS
The percentages of improvement were 40.2% in total IPSS, 40.6% in obstructive symptom, 39.4% in irritative symptom, 44.7% in QoL, 124.8% in Qmax, 33.5% in RUV(p<0.05). Three patients(9.1%) experienced acute urinary retention and BPH-related surgery was performed in 6 patients (18.2%).
CONCLUSIONS
Our study revealed that long-term treatment over 6 years with alpha-blocker resulted in significant improvements in the IPSS, QoL, Qmax and RUV.

Keyword

Benign prostatic hyperplasia; Doxazosin

MeSH Terms

Male
Humans

Reference

1. Macfarlane GJ, Sagnier PP, Richard F, Teillac P, Botto H, Boyle P. Determinants of treatment-seeking behaviour for urinary symptoms in older men. Br J Urol. 1995. 76:714–718.

2. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978. 50:551–554.

3. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology. 1995. 45:398–405.

4. Abrams PH, Shah PJ, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol. 1982. 54:527–530.

5. Park CH, Chang HS, Oh BY, Kim HJ, Sul CK, Chung SK, et al. One year long-term evaluation of tamsulosin HCL (0.2 mg) in lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a Korean, multicenter, single-blind study. J Korean Continence Soc. 2004. 8:1–8.

6. Chung BH, Kim YS, Hong SJ. 12-month follow-up study to evaluate the efficacy and safety of doxazosin GITS in patients with benign prostatic hyperplasia. Korean J Urol. 2005. 46:451–457.

7. Chung BH, Chung HJ, Hong SJ, Lee MS. Doxazosin in the symptomatic treatment of benign prostatic hyperplasia. Korean J Urol. 1999. 40:607–612.

8. Noh JH, Oh BY, Park YI. The efficacy of combination therapy of 5α-reductase inhibitor and α1-adrenergic blocker in benign prostate hyperplasia. Korean J Urol. 1998. 39:1190–1196.

9. Joung JY, Park JK, Park CH, Lee JG, Chung BH, Hong SJ, et al. The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia: the effect on lower urinary tract symptoms and nocturia. Korean J Urol. 2006. 47:1–6.

10. Chung BH, Chung HJ, Hong SJ. Long-term efficacy and safety of terazosin in the symptomatic treatment of benign prostatic hyperplasia. Korean J Androl. 1999. 17:45–50.

11. Lee JJ, Hong SJ. The effect of prazosin as a first-line therapy for the symptomatic benign prostatic hypertrophy. Korean J Urol. 1993. 34:855–859.

12. Dutkiewicz S. Long-term treatment with doxazosin in men with benign prostatic hyperplasia: 10-year follow-up. Int Urol Nephrol. 2004. 36:169–173.

13. Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, et al. Alfuzosin 10mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int. 2008. 101:847–852.

14. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003. 170:498–502.

15. Kim CI, Chang HS, Kim BK, Park CH. Long-term results of medical treatment in benign prostatic hyperplasia. Urology. 2006. 68:1015–1019.